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Abstract Objectives: Human migration and concomitant HIV infections are likely
to bring about major changes in the epidemiology of zoonotic parasitic infections.
Human African trypanosomiasis (HAT) control is particularly fraught with intricacies.
The primarily zoonotic form, T.b. rhodesiense, and the non-zoonotic T.b. gambiense co-
exist in Northern Uganda, leading to a potential geographic and genetic overlap of the
two foci. This region also has the highest HIV prevalence in Uganda plus poor food
security. We examine the bottlenecks facing the control program in a changed political
and economic context. Method: We searched the literature in July 2015 using three
databases: MEDLINE, Google Scholar, and Web of Science. Findings: Decentralized
zoonotic HAT control for animal reservoirs and vectors compromise sustainability of the
control programs. Human transmission potential may be underestimated in a regionwith
other endemic diseases and where an HIV-HATepidemic, could merge two strains. Con-
clusion: Our comprehensive literature review concludes that enhanced collaboration is
imperative not only between human and animal health specialists, but also with political
science. Multi-sectorial collaborations may need to be nurtured within existing opera-
tional national HIV prevention frameworks, with an integrated surveillance framework.
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Introduction
Neglected tropical diseases (NTDs) affect approximately 1.4 billion
people living below the World Bank poverty level of US$1.25 per day.1
The World Health Organization (WHO) identified 17 NTDs, of which
three are zoonotic and vector-borne: Chagas, human African trypanoso-
miasis (HAT), and zoonotic visceral leishmaniasis (ZVL). While Chagas
vector control using pyrethroid insecticides has been successful for
decades,2,3 HAT control is fraught with challenges and complexities.
HAT is a systemic parasitic disease, transmitted to humans by tsetse
flies, that is endemic in sub-Saharan Africa where at least 60 million
people are at-risk of infection.4 While the early stage is characterized by
a non-specific febrile illness, it progresses to neuropsychiatric distur-
bances in the late stage, resulting in coma and death if untreated.5 The
only region where the two strains of HAT, the primarily zoonotic form,
T.b. rhodesiense, and the non-zoonotic form, T.b. gambiense, are
documented to co-exist is in Northern Uganda. Because the two
parasites require different drug treatments and cannot be differentiated
by microscopy alone, treatment has depended on the geographic loca-
tion, creating a significant public health problem.6 Northern Uganda
also has the highest HIV prevalence in the country,7,8 high endemicity for
other tropical infections, and poor food security.9
HAT has spread in Uganda during a period of structural adjustment
programs (SAPs) promoted since the early 1980s by the World Bank and
International Monetary Fund to achieve accelerated economic growth in
Africa.10 In Uganda, SAPs in the late 1980s saw the withdrawal of state-
subsidies in animal health, the privatization of veterinary services, and
liberalization of the veterinary drug market.11 Simultaneously, health care
decentralization was promoted by the World Bank to reduce inequities in
service provision and inefficiencies in centrally controlled systems.12
The objectives of our review were to describe the epidemiological
profile of HAT in Uganda, to describe and assess the Ugandan surveil-
lance and control strategies, and to identify knowledge gaps and
research opportunities.
Methods
We searched the literature in July 2015, using three electronic databases:
MEDLINE (1948–July 2015), Google Scholar, and Web of Science
Menon et al
52 © 2016 Macmillan Publishers Ltd. 0197-5897 Journal of Public Health Policy Vol. 37, 1, 51–67
(1899–July 2015). We retrieved papers in English using medical subject
headings. We undertook an additional manual search to include the
bibliographies of the retrieved references.
The terms we used for the search included: ‘decentralization AND
health care AND Uganda’; ‘human African trypanosomiasis OR HAT
OR Tb rhodesiense OR sleeping disease AND control’; ‘human African
trypanosomiasis OR HAT OR Tb rhodesienseOR sleeping disease’; and
‘HIV OR Human Immunedeficiency Virus OR AIDS OR Acquired
Immune deficiency syndrome OR co-infections’.
HAT Profile
HAT is a parasitic disease caused by Trypanosoma brucei that is
transmitted by the tsetse fly (Glossina species), found mostly in rural
settings in Africa.13 The Trypanosoma brucei (T.b.) complex includes
three morphologically identical subspecies: T.b. brucei, T.b. rhodesiense,
and T.b. gambiense. T.b. rhodesiense and T.b. gambiense cause HAT.14
Both strains cause HATand the illnesses are both called sleeping disease,
but rhodesiense and gambiense are different diseases – clinically and
epidemiologically.15 T.b. rhodesiense is the more virulent and acute form
of HAT, and is lethal within weeks or months if left untreated.16 The
main reservoirs for T.b. rhodesiense are domestic cattle and wild
animals,17 with the tsetse flies primarily feeding on the legs of cattle.18
The tsetse fly, Glossina palpalis, is the vector responsible for the
transmission of T. gambiense. G. morsitans, the predominant vector of
T. rhodesiense, inhabits much of mid-continental Africa between the
Sahara and the Kalahari deserts.19 It can live for up to 6 months, taking a
blood-meal every 2–3 days.20
Clinical features
Both infections, T.b. rhodesiense and T.b. gambiense, are characterized
by an early stage – the preliminary haematolymphatic stage – that entails
bouts of fever, headaches, joint pains, and itching, during which
trypanosomes can be found circulating in the blood and in lymph nodes.
This gives rise to hypergammaglobulinemia.21 The second stage – the
meningoencephalitis stage – occurs when the parasites cross the blood
brain barrier. Symptoms, including behavior change, confusion, and
poor coordination appear,22 and death ensues. Development of the
Revisiting zoonotic human African trypanosomiasis control in Uganda
53© 2016 Macmillan Publishers Ltd. 0197-5897 Journal of Public Health Policy Vol. 37, 1, 51–67
infection in Rhodesian sleeping sickness is similar to that in the Gambian
strain, except that T.b. gambiense is chronic. There is little lymphadeno-
pathy. A limited literature discusses co-infections, including with HIV, in
HAT patients – prevalence, effects on clinical presentation, and disease
outcome.22
Diagnosis of HAT
The point-of-care Card Agglutination Test (CATT) for mass screening of
T.b. gambiense has been a major breakthrough, reducing the number of
parasitological examinations made by microscope. It has relatively high
sensitivity (84.0 per cent) and specificity (98.5 per cent).23
A case of T.b. rhodesiense can be confirmed by microscopic detection
of trypanosomes in the blood, lymph, or cerebrospinal fluid at reference
centers in Uganda, where there are highly trained technicians.24–26
Conventional microscopy has low sensitivity, missing up to 30 per cent
of cases.27 In rural, under-resourced areas, poorly equipped to deal with
HAT detection and management, clinical diagnosis is relied upon.28
Among symptomatic individuals with T.b. rhodesiense,29 reluctance to
seek health services because of the cost of patient services,30 makes early
diagnosis among symptomatic individuals less common.30
Treatment
Pentamidine, the first line drug for T.b. gambiense, is not effective
against early stage T.b. rhodesiense. Another drug, suramin, is adminis-
tered. Late stage cases of both diseases are treated with melarsoprol.
Eflornithine is administered for T.b. gambiense only in case of treatment
failure.31 Two obstacles limit their effectiveness: considerable toxicity32
and the specific action being limited to a particular stage. This requires
systemic stage determination by trained staff.33
Epidemiology
In Sub-Saharan Africa, T.b. gambiense accounts for the vast majority
(98 per cent) of reported HAT cases.34 The overall incidence of HAT has
decreased across Africa during the past 5 years.34 T.b. rhodesiense, on
the contrary, has expanded to new territories in northwestern Uganda,
where the geographic distance between the two strains is diminishing.30
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From 2000 to 2009, Uganda reported a total of 3775 T.b. gambiense
cases, which represented 2 per cent of the total burden in Africa, while a
total of 2848 T.b. rhodesiense cases were reported during that same time
period, representing 56 per cent of the total African cases.35 In Uganda,
44 cases of T.b. rhodesiense were reported to the WHO in 2011.36
Northwest Uganda, where both strains are currently less than 100 km
apart,37 is considered a high transmission intensity setting.36 This region
in Uganda is also characterized by high HIV prevalence. A recent
seroprevalence survey found 12.8 per cent prevalence of HIV in people
in a post-emergency phase transition camp in northwestern Uganda.38
In Uganda, several risk factors have been associated with the transmis-
sion of HAT. For T.b. gambiense, where humans are its main reservoir,
some data39–41 suggest a possible role played by asymptomatic human
beings or animals as additional reservoirs. For T.b. gambiense, while the
tsetse fly has a relatively low competence as a vector given the low
parasitemia in humans, the long duration of human infection is considered
sufficient to maintain a human–fly–human transmission cycle.42
T.b. rhodesiense can occur in both endemic and epidemic forms.30
Epidemics for T.b. rhodesiense have been frequently linked to social or
environmental disruptions that force people and livestock to move to
areas where there is increased contact with tsetse flies, that can trigger
local outbreaks of the disease.43–47 Such disruptions have played a
pivotal role in epidemiological shifts of T.b. rhodesiense in the north-
western part of the country.48
With the cessation of the military conflict in northern Uganda, efforts
to restock post-conflict districts with cattle have led to further expan-
sion of T.b. rhodesiense to northern districts already endemic for
T.b. gambiense.47 Upon returning home after the conflict, internally
displaced persons faced an increased risk due to tsetse habitat that had
enlarged during their absence.46 Livestock markets have also been
identified as a risk factor in increasing prevalence among both humans
and cattle. Movement of untreated cattle brings the disease to new areas,49
with increased risk for those residing near the cattle markets.50,51
Control and surveillance strategies
From the time of British colonial until the onset of the Great African
Depression in the 1980s, HAT control and prevention in Uganda were
centrally managed.52,53 Control and prevention activities included
Revisiting zoonotic human African trypanosomiasis control in Uganda
55© 2016 Macmillan Publishers Ltd. 0197-5897 Journal of Public Health Policy Vol. 37, 1, 51–67
centralized, technology-driven vector and reservoir control strategies,
such as ground and aerial insecticide spraying of high-risk areas, mass
land clearing, elimination of wildlife in affected zones, and settlement
relocation to tsetse-free zones.54 With competing priorities, including
civil war and efforts to stem the AIDS epidemic in Uganda, as well as
dwindling international commitment, HAT control and prevention
activities could not be sustained, given the resource constraints.55 More-
over, a growing environmental lobby concerned about the widespread
use of insecticide and land clearing practices criticized these activities.56
In addition, there was a surge of community participation programs,
such as the approach used for tsetse control operations, that contrasted
with the traditional top-down campaigns.57
From 1997 to 1999, the Ministry of Health (MoH) underwent an
overhaul, reducing its functions to policymaking, planning, quality
assurance, capacity development, technical support, and coordination
of services rendered at national level.58 The objective of decentralization
of health services administration to district level was to ameliorate
quality and accessibility of health services.59 Under decentralization,
activities once considered the remit of the State Veterinary Services
devolved to community-based trypanosome control, including pesticide
use.54 Since its creation in 1999, the National Sleeping Sickness Control
Program has been in charge of surveillance and coordinating HAT
control activities.56 Health care facilities became responsible for diag-
nosis and treatment of HAT. They continued to send their surveillance
reports to the national program as they had before decentralization.56
Integration within primary health care was intended to increase passive
case-finding,60 by making health care more accessible in rural areas.
Ugandan health reforms of the 1980s included cost sharing with patients
for treatment and diagnosis. The national surveillance program relies on
case reports from the health care system. The true burden of T.b.
rhodesiense is likely to be underestimated in this passive system. Not all
individuals with HATwill seek diagnosis and treatment, and diagnostic
tools remain somewhat insensitive.22
Treatment of cattle
HAT control and prevention in Uganda includes mass treatment of cattle
with trypanocides to destroy trypanosomes plus insecticide spraying of
cattle to control the tsetse flies. Long-term success of T.b. rhodesiense
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control requires both treatment of the animal reservoir to eliminate
pathogen that can infect humans plus sustained efforts to prevent
reinfection of these animals.52 The Stamp Out Sleeping Sickness (SOS)
campaign (a public–private partnership, established by Ceva Santé
Animale, Coordinating Office for Control of Trypanosomiasis in
Uganda, the Centre for Infectious Diseases, University of Edinburgh, IK
Investment Partners/IKARE, and Makerere University, Faculty of Veter-
inaryMedicine in 2006) carries out cattle treatment with insecticides and
trypanocides to manage the spread of the disease. Incidence had
increased as a result of the restructuring and downsizing of the govern-
ment’s veterinary staff at the national level.61 Within its framework and
at the community level, veterinary students raise awareness, establish
village-based spray teams, and sell veterinary products.55 This commu-
nity initiative reduced the spread of T.b. rhodesiense and reduced the
prevalence of trypanosomes in cattle by 75 per cent62 since the start of
the S.O.S campaign.55 The Co-ordinating Office for Control of Trypa-
nosomiasis plans to implement large-scale use of intensive cattle treat-
ments using trypanocides plus the restricted application method (RAP)
– application of pour-on insecticides restricted to the legs – to reduce T.b.
rhodesiense across 32 high-risk districts and to promote RAP adoption
in the lower risk districts.55 A mathematical model has suggested that if
tsetse flies fed exclusively on cattle and people, only 20 per cent of cattle
would need to be treated with insecticide for the Basic Reproductive Rate
of the disease to become less than one (R0< 1). Administration of
trypanocides would be less effective and (R0<1) could only be attained
by treating approximately 65 per cent of cattle with trypanocides.63
Trypanocides
Uganda’s initial control strategy aimed to eliminate the human infective
parasites from cattle in five districts of northern Uganda, free of charge
to the farmer.55 To attain sustainability, Uganda moved from a top-down
mass treatment strategy to the current bottom-up farmer and commu-
nity-based approach.55 But farmers responsible for livestock control of
HAT are often ill-prepared to adopt changes in practice and treatment.
Often they cannot differentiate HAT from other endemic diseases.64
Decentralization of State Veterinary Services has led to veterinary
drugs being sold freely by private agro-veterinary shops and by poorly
trained animal health workers.65 The withdrawal of state-subsidies in
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animal health as an element of SAPs in the late 1980s11 has resulted in
many farmers self-medicating cattle, likely increasing the risk of drug
resistance due to inappropriate dosage and length of treatment.66 Poor
adherence to the national policy recommending administration of
trypanocidal drugs before the movement of cattle from rhodesiense-
endemic areas in the southeast of Uganda may be contributing in recent
years to the northwards spread of the disease.67
Insecticide
Because tsetse flies feed mostly on the legs of cattle, the application of
pour-on insecticides is restricted to the legs, known as the RAP. It enables
farmers to save up to 80 per cent of the product.68 To sustain gains
achieved through mass treatment with trypanocides, community-based
networks of insecticide sprayers continue to spray 15–20 per cent of
cattle monthly.54 The community-based insecticide approach may be
limited by farmers concern about product price.69 One study found that
farmers bought almost twice the volume of a tick insecticide that was not
effective against tsetse flies.69 Not a single community-based project
using tsetse insecticide traps has been sustained by communities,
suggesting how difficult it is to involve and sustain farmers’ participation
in relatively low-cost intervention in resource-poor areas.70 Many other
uncertainties remain and need to be examined.
Knowledge gaps
Estimates of true burden of T.b. rhodesiense in Uganda
Estimating the true burden of zoonotic HAT is hampered by relying on
passive surveillance that is dependent on health seeking behaviors, the
availability and appropriate use of diagnostic equipment, and the accu-
racy of HAT diagnosis. Active surveillance has had a positive impact on
reducing the incidence of T.b. gambiense in other regions of Africa where
mobile teams undertake population screening.71 Active case finding also
allows authorities to make drug resistance monitoring a higher priority.
This approach allows Uganda to understand the true burden of
T.b. rhodesiense in endemic areas. Then results could be compared to
passive case finding to understand the extent to which the active approach
is more effective. Cost-effectiveness could be compared.
Menon et al
58 © 2016 Macmillan Publishers Ltd. 0197-5897 Journal of Public Health Policy Vol. 37, 1, 51–67
Effects of co-infection with both forms – Disease progression, treatment,
and diagnostics
As geographic overlap of both HAT diseases seems very plausible,
understanding the disease progression of a mixed infection, as well as
treatment and diagnostic implications deserves to be fully explored.6
Mixed infections may further compound the problem of drug resistance
to melarsoprol, because of inappropriate treatment. Molecular testing,
requiring better laboratory infrastructure, would allow the two strains to
be identified genetically and could reduce inappropriate treatment.
Co-infection with other endemic diseases
How do co-infections with other endemic diseases affect immunity, drug
toxicity, and drug resistance? A recent study showed that clinical
presentation and outcome of HAT were not influenced significantly by
concurrent infections – 37.2 per cent were co-infected with malaria.22
This finding, however, deserves to be corroborated by further research.
Clinical guidelines on co-infection management need to be developed,72
to support decision making and differential diagnosis in health facilities.
Role of humans as a reservoir with T.b. rhodesiense
What is the contribution of humans in the transmission of T.b.
rhodesiense? Researchers currently believe it to be insignificant, but
under-reporting estimates have not been modeled in the northwest,73 a
region characterized by a high prevalence of other endemic diseases that
may complicate clinical diagnosis. Such uncertainties may increase
understanding of the importance of the human reservoir.74 Research
gaps will need to be addressed for transmission potential to be reassessed
and improve the control and prevention of HAT.
Assessing the burden of T.b. rhodesiense in a setting with high food
insecurity
In northwestern Uganda, almost 50 per cent of patients manifested a very
poor nutritional status (48 per cent had BMI<16.5) as food security
is very poor.9 HAT may be over reported because of similarities between
the neurological symptoms of undernutrition and of T.b. rhodesiense.
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A clinical diagnostic algorithm will be needed to differentiate the sequelae
of undernutrition from that of T.b. rhodesiense.
Co-infection with HIV – Disease progression, treatment, diagnostics
With northwestern spread of the two strains, HIV co-infection, has
become a concern because of the high prevalence of HIV in northwestern
Uganda.75,76 Few data exist on HIV co-infections in Uganda. A recent
study showed that in 18 individuals with HAT, three had HIV (17 per
cent).22
In a 2015 study, clinical presentation and outcomes of HIV-HAT co-
infection were not influenced significantly by concurrent infections.22
Other studies found that HIV-T.b. gambiense co-infection negatively
affected HAT treatment efficacy and outcomes.69,77 Although unknown
for T.b. rhodesiense, T.b. gambiense has been shown to lower the
sensitivity of HIV diagnostics significantly.77,78 HIV and co-infection
with visceral leishmaniasis have been shown to increase the transmissi-
bility of the disease79 and HIV viral load.80 Is this synergistic effect also
found in HIV-HAT co-infected individuals? One study noted that
melarsoprol stimulated the replication of several strains of HIV-1,
potentially compromising the efficacy of HIV treatment and increasing
HIV transmission.72,81 Further research into HIV-HAT co-infections,
including about the impact on HIV transmission and diagnostics are
imperative; so too is development of clinical management guidelines for
HIV-HAT co-infection.
Drivers of drug resistance:
Trypanocide resistance in humans has been detected in Uganda. One
study found that up to 30 per cent of patients in some parts of
northwestern Uganda showed resistance to melarsoprol.82 The epide-
miology of drug resistance to melarsoprol deserves to be elucidated.
Emergence of drug-resistant trypanosome strains in HIV-infected indivi-
duals warrants study of the mechanisms of trypanosome resistance.
Drug resistance needs to be monitored in conjunction with trypanocide
resistance monitoring in livestock. Such resistance has been reported
from multiple regional foci.83,84 Resistance to one of the trypanocidal
compounds, diamidine, induced by treating livestock, has been docu-
mented in patients.85,86
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Conclusion
There have been major advances in zoonotic HAT control in Uganda,
exemplified by the S.O.S campaign focus on the animal reservoir.
Decentralization of control programs have strengthened rural health
centers in Uganda,87 but the lack of effective national veterinary super-
vision may have contributed to failure to control the spread of T.b.
rhodesiense.88 Community-based approaches may have favoured resis-
tance to veterinary trypanocides, which have the potential to render
HAT drugs ineffective.
Early diagnosis and treatment is essential for the patient, but is likely
to have limited impact on transmission if the main animal reservoir or
insect vectors are not controlled.89 Undetected HAT and unsuccessful
treatment of HAT in individuals may increase the importance of the
human reservoir. The two strains are now found in close proximity in
northwestern Uganda. What are the implications of this? They need to
be fully understood, along with the interaction between T.b. rhodesiense
and HIV, and other endemic diseases.
The One Health approach to disease control, described in 2004, is
based upon a premise of collaboration between human and veterinary
medicine.90 Important for HAT control and for Uganda, collaboration
would benefit from inclusion of ecologists, epidemiologists, veterinar-
ians, physicians and nurses, laboratory technicians, HIV specialists,
entomologists, and political scientists. A multi-level, multi-disciplinary
collaboration needs to be established if the world is to achieve the WHO
goal to eliminate HAT as a public health problem by 2020.
The MoH must remain empowered to oversee coordination of
technical assistance and to enforce veterinary regulation. It should
oversee clinical training of staff for the diagnosis and management of
HAT in humans, as well as making diagnostic equipment and treatment
readily available. The MoH should strengthen passive surveillance of
T.b. rhodesiense or transition to active surveillance in humans, akin
to the transition made for T.b. gambiense. In epidemic prone areas,
this approach may be more cost-effective.91 Surveillance should include
resistance monitoring: monitoring resistance to treatment in humans
and in animals, as well as insecticide resistance. Uganda’s program
must be sufficiently decentralized so that preventive measures can be
tailored to locally-derived epidemiology obtained from communities.
Veterinary authorities and the MoH must create a joint monitoring and
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evaluation framework. Timely access to high quality surveillance data,
including information on interventions, resistance, and co-infections is
imperative.
Formidable challenges face those trying to control HAT. Unless a
balance is struck between government and community involvement,
HAT community-based programs may remain less than fully effective.
HAT control begs for a wider integrated control framework, one that
considers the potential synergy of overlapping HIV prevalence, poor
food security, and other endemic tropical diseases.
About the Authors
Sonia Menon, MA (International Relations), MPH, and MSc (Infectious
diseases from the London School of Hygiene and Tropical Medicine,
LSHTM), is currently a PhD candidate in Epidemiology at the Inter-
national Centre of Reproductive Health at Ghent University. While
writing this article she worked as an Epidemiologist/research assistant
in Biostatistics and Occupational Health at McGill University, Quebec,
Canada. Her principle interests are tropical clinical epidemiology and
HIV co-infection with neglected tropical diseases.
Rossi Rodolfo, MSc (Public Health) and MSc (Epidemiology, LSHTM),
has worked as humanitarian worker, in primary and hospital care, and
in field research in conflict areas in South Sudan, Rwanda, Liberia,
Uganda, Somalia, Congo, and Zimbabwe since 2001.
Leon Nshimyumukiza, MD (general medicine from University of
Rwanda) and MSc (Community Health from Laval University, Quebec,
Canada), is a PhD Candidate in Epidemiology at Laval University and a
junior lecturer of Health economics there. As general practitioner he
worked hospitals in Kigali, Rwanda, from 2002 to 2007.
Kate Zinszer, PhD, is a postdoctorate fellow with HealthMap at Boston
Children's Hospital and Harvard Medical School. She worked to
develop and evaluate malaria forecasting models for Uganda as a
doctoral student at McGill after serving as communicable disease and
field epidemiologist with the Public Health Agency of Canada and
Vancouver Coastal Health Authority.
Menon et al
62 © 2016 Macmillan Publishers Ltd. 0197-5897 Journal of Public Health Policy Vol. 37, 1, 51–67
References
1. Hotez, P.J. (2011) The neglected tropical diseases and the neglected infections of poverty:
Overview of their common features, global disease burden and distribution, new control tools,
and prospects fordisease elimination. In:Institute of Medicine (US) Forum onMicrobial Threats
The Causes and Impacts of Neglected Tropical and Zoonotic Diseases: Opportunities for
Integrated Intervention Strategies. Washington (DC): National Academies Press.
2. World Health Organization – WHO. (2002) Control of Chagas Disease: Second Report of the
WHO Expert Committee. WHO Tech Rep Ser 905: i–vi 1–109, Geneva, Switzerland.
3. Moncayo, A. and Silveira, A.C. (2009) Current epidemiological trends for Chagas disease in
Latin America and future challenges in epidemiology, surveillance and health policy.Memórias
do Instituto Oswaldo Cruz 104(Suppl.1): 17–30.
4. Fèvre, E.M., Wissmann, B.V., Welburn, S.C. and Lutumba, P. (2008) The burden of human
African trypanosomiasis. PLoS Neglected Tropical Diseases 2(12): article e333.
5. Brun, R., Blum, J., Chappuis, F. and Burri, C. (2010) Human African trypanosomiasis.
The Lancet 375(9709): 148–159.
6. Fevre, E., Picozzi, K., Jannin, J., Welburn, S. and Maudlin, I. (2006) Human African
trypanosomiasis: Epidemiology and control. Advances in Parasitology 61: 167–221.
7. Simarro, P.P., Diarra, A., Ruiz Postigo, J.A., Franco, J.R. and Jannin, J.G. (2011) The human
African trypanosomiasis control and surveillance programme of the world health organization
2000–2009: The way forward. PLoS Neglected Tropical Diseases 5(2): e1007.
8. Picozzi, K. et al (2005) Sleeping sickness in Uganda: A thin line between two fatal diseases.
British Medical Journal 331: 1238–1241.
9. Kuepfer, I., Hhary, E.P., Allan, M., Edielu, A., Burri, C. and Blum, J.A. (2011) Clinical
presentation of T.b. rhodesiense sleeping sickness in second stage patients from Tanzania and
Uganda. PLoS Neglected Tropical Diseases 5(3): e968.
10. WHO. (2015) Trade, foreign policy, diplomacy, and health: Structural adjustment programs,
http://www.who.int/trade/glossary/story084/en/, accessed 2 April 2015.
11. Leonard, D. (2000) Africa’s Changing Markets for Health and Veterinarian Services: The New
Institutional Issues. London: Palgrave Macmillian.
12. Menon, S. (2006) Decentralization and health care in the former Yugoslav Republic of
Macedonia. International Journal of Health Planning and Management 21(1): 3–21.
13. CDC. (2012) African trypanosomiasis, also known as sleeping disease, http://www.cdc.gov/
parasites/sleepingsickness/, accessed 7 April 2015.
14. Duffy, C.W. et al (2013) Population genetics of trypanosoma brucei rhodesiense: Clonality and
diversity within and between foci. Masiga DK, ed. PLoS Neglected Tropical Diseases 7(11):
e2526.
15. Fevre, E.M., Picozzi, K., Jannin, J., Welburn, S.C. and Maudlin, I. (2006) Human African
trypanosomiasis: Epidemiology and control. Advances in Parasitology 61: 167–221.
16. Chappuis, F., Loutan, L., Simarro, P., Lejon, V. and Büscher, P. (2005) Options for
field diagnosis of human African trypanosomiasis. Clinical Microbiology Reviews 18(1):
133–146.
17. WHO. (2015) Trypanosomiasis, http://www.who.int/trypanosomiasis_african/en/, accessed 7
April 2015.
18. Muhanguzi, D. et al (2014) Improvements on restricted insecticide application protocol for
control of human and animal african trypanosomiasis in eastern Uganda. PLoS Neglected
Tropical Diseases 8(10): e3284.
19. Rogers, D.J., Hay, S.I. and Packer, M.J. (1996) Predicting the distribution of tsetse flies in West
Africa using temporal Fourier processed meteorological satellite data. Annals of Tropical
Medicine and Parasitology 90(3): 225–241.
Revisiting zoonotic human African trypanosomiasis control in Uganda
63© 2016 Macmillan Publishers Ltd. 0197-5897 Journal of Public Health Policy Vol. 37, 1, 51–67
20. WHO. (1998) Control and surveillance of African trypanosomiasis: Report of a WHO expert
committee, http://apps.who.int/iris/bitstream/10665/42087/1/WHO_TRS_881.pdf, accessed
18 February 2015.
21. WHO. (2015) Fact sheet N°259 Human African trypanosomiasis, http://www.who.int/
mediacentre/factsheets/fs259/en/, accessed 18 June 2015.
22. Kato, C.D., Nanteza, A., Mugasa, C., Edyelu, A., Matovu, E. and Alibu, V.P. (2015) Clinical
profiles, disease outcome and co-morbidities among T. b. rhodesiense sleeping sickness patients
in Uganda. PloS One 10(2): e0118370.
23. Matovu, E. et al (2010) Phase II evaluation of sensitivity and specificity of PCR and NASBA
followed by oligochromatography for diagnosis of human African trypanosomiasis in clinical
samples from D.R. Congo and Uganda. PLoS Neglected Tropical Diseases 4(7): e737.
24. Aiyedun, B.A. et al (1976) Parallel evaluation of serological tests applied in African
trypanosomiasis: A WHO collaborative study. Bulletin of the World Health Organization
54(2): 141–147.
25. Kakoma, I., Bulsara, M., Boatin, B. and Wurapa, F.K. (1985) Diagnostic value of the indirect
immunofluorescent antibody test for trypanosomiasis in Zambia. American Journal of Tropical
Medicine and Hygiene 34(1): 69–72.
26. Komba, E., Odiit, M., Mbulamberi, D.B., Chimfwembe, E.C. and Nantulya, V.M. (1992)
Multicentre evaluation of an antigen-detection ELISA for the diagnosis of trypanosoma brucei
rhodesiense sleeping sickness. Bulletin of the World Health Organization 70(1): 57–61.
27. Robays, J.M.M., Belengue, P., Van der Stuyft, P. and Boelaert, M. (2004) The effectiveness of
active population screening and treatment for sleeping sickness control in the democratic
Republic of Congo. International Journal of Tropical Medicine and Public Health 9: 542–550.
28. Simarro, P.P., Jannin, J. and Cattand, P. (2008) Eliminating human African trypanosomiasis:
Where do we stand and what comes next? PLoS Medicine 5(2): e55.
29. Odiit, M., Shaw, A., Welburn, S.C., Fèvre, E.M., Coleman, P.G. and McDermott, J.J. (2004)
Assessing the patterns of health-seeking behaviour and awareness among sleeping-sickness
patients in eastern Uganda. Annals of Tropical Medicine & Parasitology 98(4): 339–348.
30. Franco, J.R., Simarro, P.P., Diarra, A. and Jannin, J.G. (2014) Epidemiology of human African
trypanosomiasis. Journal of Clinical Epidemiology 6: 257–275. doi:10.2147/CLEP.S39728.
pmid:25125985.
31. Picozzi, K. and Fèvre, E.M. (2005) Sleeping sickness in Uganda: A thin line between two fatal
diseases. British Medical Journal. PMCID: PMC1289320. doi: 10.1136/bmj.331.7527.1238.
32. WHO. (2014) Human African trypanosomiasis symptoms, diagnosis & treatment, http://www.
who.int/mediacentre/factsheets/fs259/en/, accessed 18 June 2015.
33. Simarro, P.P., Jannin, J. and Cattand, P. (2008) Eliminating human African trypanosomiasis:
Where do we stand and what comes next? PLoS Medicine 5(2): e55.
34. World Health Organization. (2006) Human African trypanosomiasis (sleeping sickness):
Epidemiological update.Weekly Epidemiological Record 81(8): 71–80.
35. Simarro, P. et al (2010) The Atlas of human African trypanosomiasis: A contribution to global
mapping of neglected tropical diseases. International Journal of Health Geographics 9: 57.
36. Simarro, P.P., Franco, J.R., Diarra, A., Ruiz Postigo, J.A. and Jannin, J. (2013) Diversity of
human African trypanosomiasis epidemiological settings requires fine-tuning control strategies
to facilitate disease elimination. Journal of Research and Reports in Tropical Medicine
4: 1–6.
37. Sistrom, M. et al (2014) Comparative genomics reveals multiple genetic backgrounds of human
pathogenicity in the trypanosoma brucei complex.Genome Biology and Evolution 6(10): 2811–2819.
38. Patel, S., Schechter, M.T., Sewankambo, N.K., Atim, S., Kiwanuka, N. and Spittal, P.M. (2014)
Lost in transition: HIV prevalence and correlates of infection among young people living in
post-emergency phase transit camps in Gulu district, Northern Uganda. PloS one 9(2): e89786.
Menon et al
64 © 2016 Macmillan Publishers Ltd. 0197-5897 Journal of Public Health Policy Vol. 37, 1, 51–67
39. Koffi, M. et al (2009) Population genetics of Trypanosoma brucei gambiense, the agent of
sleeping sickness in Western Africa. Proceedings of the National Academy of Sciences of the
United States of America 106(1): 209–214.
40. Cordon-Obras, C. et al (2010) Screening of trypanosoma brucei gambiense in domestic
livestock and tsetse flies from an insular endemic focus (Luba, Equatorial Guinea). PLoS
Neglected Tropical Diseases 4(6): e704.
41. Funk, S., Nishiura, H., Heesterbeek, H., Edmunds, W.J. and Checchi, F. (2010) Identifying
transmission cycles at the human-animal interface: The role of animal reservoirs in maintaining
gambiense human african trypanosomiasis. PLoS Computational Biology. 2013 9(1):
e1002855.
42. Baker, R.D. (1991) Modelling the probability of a single trypanosome infecting a tsetse fly.
Annals of Tropical Medicine & Parasitology 85(4): 413–415.
43. Hide, G., Tait, A., Maudlin, I. and Welburn, S.C. (1996) The origins, dynamics and genera-
tion of trypanosoma brucei rhodesiense epidemics in East Africa. Parasitology Today 12(2):
50–55.
44. Jelinek, T. et al (2002) European network on imported infectious disease surveillance cluster of
African trypanosomiasis in travelers to Tanzanian national parks. Emerging Infectious Diseases
8(6): 634–635.
45. Kaare, M.T. et al (2007) Sleeping sickness – A re-emerging disease in the Serengeti? Travel
Medicine and Infectious Disease 5(2): 117–124.
46. Berrang Ford, L. (2007) Civil conflict and sleeping sickness in Africa in general and Uganda in
particular. Conflict and Health 1: 6.
47. Selby, R., Bardosh, K., Picozzi, K., Waiswa, C. andWelburn, S.C. (2013) Cattle movements and
trypanosomes: Restocking efforts and the spread of trypanosoma brucei rhodesiense sleeping
sickness in post-conflict Uganda. Parasites & Vectors 6(1): 281.
48. Fèvre, E., Coleman, P., Welburn, S. andMaudlin, I. (2004) Reanalyzing the 1900–1920 sleeping
sickness epidemic in Uganda. Emerging Infectious Diseases 10(4): 567–573.
49. Batchelor, N.A. et al (2009) Spatial predictions of rhodesian human African trypanosomiasis
(sleeping sickness) prevalence in Kaberamaido and Dokolo, two newly affected districts of
Uganda. PLoS Neglected Tropical Diseases 3(12): e563.
50. Zoller, T., Fèvre, E.M., Welburn, S.C., Odiit, M. and Coleman, P.G. (2008) Analysis of risk
factors for T. brucei rhodesiense sleeping sickness within villages in south-east Uganda.
BMC Infectious Diseases 8(88): 1–9.
51. WHO. (2015) Human African trypanosomiasis, the transmission cycle, http://www.who.int/
trypanosomiasis_african/transmission_cycle/en/, accessed 10 May 2015.
52. Bardosh, K., Waiswa, C. and Welburn, S.C. (2013) Conflict of interest: Use of pyrethroids and
amidines against tsetse and ticks in zoonotic sleeping sickness endemic areas of Uganda.
Parasites & Vectors 6: 204.
53. Mitchinson, Robin (2003) Devolution in Uganda: An experiment in local service delivery.
Public Administration and Development 23(3): 241–248.
54. Maudlin, I. (2006) African trypanosomiasis. Annals of Tropical Medicine & Parasitology
100(8): 679–701.
55. Uilenberg, G. (1998) A field guide for the diagnosis, treatment and prevention of African animal
trypanosomes. Chapter 1 African Animal Trypanosomes. Rome: FAO Corporate Document
Repository.
56. Kotlyar, S. (2010) Recommendations for control of East African sleeping sickness in Uganda.
Journal of Global Infectious Diseases 2(1): 43–48. doi:10.4103/0974-777X.59250.
57. Grace, D. (2003) Working Paper 2, (March) Participative Trypanosomiasis Control in Burkina
Faso; Lessons Learned and Way Forward; Ouagadougou, Burkina Faso, International
Livestock Research Institute.
Revisiting zoonotic human African trypanosomiasis control in Uganda
65© 2016 Macmillan Publishers Ltd. 0197-5897 Journal of Public Health Policy Vol. 37, 1, 51–67
58. Jeppsson, A., Ostergren, P.O. and Hagstrom, B. (2003) Restructuring a ministry of health,
an issue of structure and process, a case study from Uganda. Health Policy and Planning
18(1): 63–73.
59. Anokbonggo, W., Ogwal- Okeng, J., Obua, C., Aupo nt, O. and Ross Dengan, D. (2004)
Impact of decentralization on health services in Uganda: A look at facility utilization,
prescribing and availability of essential drugs. East African Medical Journal (Suppl:S2-S7): S27.
60. Pepin, J., Guern, C., Milor, d.F. and Mpi, a.B. (1989) Integratio n d e l a lutt e contr e l a
trypanosomias e humain e africain e dan s u n resea u d e centre s d e sant e polyvalents. Bull
World Health Organ 67(3): 301–308.
61. Morton, J. (2010) The innovation trajectory of sleeping sickness control in Uganda: Research
knowledge in its context. RiU Discussion Paper Series Paper 09. Available for download at:
http://www.researchintouse.com/bestbets/bb31sleepingsickness.html, accessed 9 August 2015.
62. Selby, R. (2011) Limiting the northerly advance of Trypanosoma brucei rhodesiense in post
conflict Uganda. PhD thesis: University of Edinburgh, UK.
63. Hargrove, J.W., Ouifki, R., Kajunguri, D., Vale, G.A. and Torr, S.J. (2012) Modeling the
control of trypanosomiasis using trypanocides or insecticide-treated livestock. PLoS Neglected
Tropical Diseases 6: e1615.
64. Chilonda, P. and Van Huylenbroeck, G. (2001) Attitude towards and uptake of veterinary
services by small-scale cattle farmers in Eastern province, Zambia. Outlook on Agriculture
30(3): 213–218.
65. Bett, B., Machila, N., Gathura, P., McDermott, J. and Eisler, M. (2004) Characteristics of shops
selling veterinary medicines in a tsetse-infested area of Kenya. Preventive Veterinary Medicine
63: 29–38.
66. Mugabi, K., Mugisha, A. and Ocaido, O. (2010) Socio-economic factors influencing the use of
acaricides on livestock: A case study of the pastoralist communities of Nakasongola district,
central Uganda. Tropical Animal Health and Production 42: 131–136.
67. Okello, A.L. and Welburn, S.C. (2014) The importance of veterinary policy in prevent-
ing the emergence and re-emergence of zoonotic disease: Examining the case of human
African trypanosomiasis in Uganda. Frontiers in Public Health 2: 218.
68. Brownlow, A.C. (2007) Evaluation of a novel method for controlling bovine trypanosomiasis.
A longitudinal study in South-East Uganda. Doctoral Thesis, School of Veterinarian Studies
University of Edinburgh, UK.
69. Meda, H.A. et al (1995) Human immunodeficiency virus infection and human African
trypanosomiasis: A case-control study in Côte d’Ivoire. Trans R Soc Trop Med Hyg
89(6): 639–643.
70. Brightwell, B., Dransfield, B., Maudlin, I., Stevenson, P. and Shaw, A. (2001) Reality vs.
rhetoric- a survey and evaluation of tsetse control in East Africa.Agriculture and Human Values
18(2): 219–233.
71. Simarro, P.P., Jannin, J. and Cattand, P. (2008) Eliminating human African trypanosomiasis:
Where do we stand and what comes next? PLoS Medicine 5(2).
72. WHO. (2007) Tech. Rep. WHO/EU/ILRI/DBL/FAO/OIE/AU. Integrated control of neglected
zoonotic diseases in Africa. Applying ‘one health’ concept. Nairobi, Kenya: ILRI Headquarters:
World Health Organization.
73. Hackett, F., Berrang Ford, L., Fevre, E. and Simarro, P. (2014) Incorporating scale dependence
in disease burden estimates: The case of human African trypanosomiasis in Uganda. PLoS
Neglected Tropical Diseases 8(2): e2704.
74. Sundar, S., Singh, V.P., Sharma, S., Makharia, M.K. and Murray, H.W. (1997) Response to
interferon-ά plus pentavalent antimony in Indian visceral leishmaniasis. Journal of Infectious
Diseases 176(4): 1117–1119.
Menon et al
66 © 2016 Macmillan Publishers Ltd. 0197-5897 Journal of Public Health Policy Vol. 37, 1, 51–67
75. Simarro, P.P. et al (2011) The human African trypanosomiasis control and surveillance
programme of the world health organization 2000–2009: The way forward. PLoS Neglected
Tropical Diseases 5: e1007.
76. Picozzi, K. et al (2005) Sleeping sickness in Uganda: A thin line between two fatal diseases.
British Medical Journal 331: 1238.
77. Pepin, J., Ethier, L., Kazadi, C., Milord, F. and Ryder, R. (1992) The impact of human
immunodeficiency virus infection on the epidemiology and treatment of Trypanosoma brucei
gambiense sleeping sickness in Nioki, Zaire. American Journal of Tropical Medi-
cine and Hygiene 47(2): 133–140.
78. Patel, S., Schechter, M.T., Sewankambo, N.K., Atim, S., Kiwanuka, N. and Spittal, P.M. (2014)
Lost in transition: HIV prevalence and correlates of infection among young people living in
post-emergency phase transit camps in Gulu district, Northern. Uganda. Roy JK, ed. PLoS One
9(2): e89786.
79. Molina, R., Lohse, J.M., Pulido, F., Laguna, F., López-Vélez, R. and Alvar, J. (2014) Infection of
sand flies by humans coinfected with Leishmania infantum and human immunodeficiency virus.
American Journal of Tropical Medicine and Hygiene 60(1): 51–53.
80. Preiser, W., Cacopardo, B., Nigro, L., Braner, J., Nunnari, A., Doerr, H.W. and Weber, B.
(1996) Immunological findings in HIV-Leishmania coinfection. Intervirology 39(4): 285–288.
81. Barat, C., Pepin, J. and Tremblay, M.J. (2011) HIV-1 replication in monocyte-derived dendritic
cells is stimulated by melarsoprol, one of the main drugs against human African trypanoso-
miasis. Journal of Molecular Biology 410(5): 1052–64.
82. Pépin, J. and Mpia, B. (2009) Randomized controlled trial of three regimens of melarsoprol in
the treatment of trypanosoma brucei gambiense trypanosomiasis. Transactions of the Royal
Society of Tropical Medicine and Hygiene 100(5): 437–441.
83. Geerts, S., Holmes, P.H., Diall, O. and Eisler, M.C. (2001) African bovine trypanosomiasis: The
problem of drug resistance. Trends Parasitol 17(4): 25–28.
84. Matovu, E., Seebeck, T., Enyaru, J.C. and Kaminsky, R. (2001) Drug resistance in Trypano-
soma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle.
Microbes and Infection 3(9): 763–770.
85. Kibona, S.N., Matemba, L., Kaboyal, J.S. and Lubega, G.W. (2006) Drug reistance of
trypanosoma b. rhodesiense isolates from Tanzania. Tropical Medicine and International
Health 11: 144–155.
86. Kagira, J.M. and Maina, N. (2007) Occurrence of multiple drug resistance in trypanosoma
brucei rhodesiense isolated from sleeping from sleeping sickness patients. Onderstepoort
Journal of Veterinary Research 74(1): 17–22.
87. Paim, J., Travassos, C., Almeida, C., Bahia, L. and Macinko, J. (2011) The Brazilian health
system: History, advances, and challenges. Lancet 377(9779): 1778–1797.
88. Welburn, S., Coleman, P., Maudlin, I., Fevre, E., Odiit, M. and Eisler, M.C. (2006) Crisis, what
crisis? Control of Rhodesian sleeping sickness. Trends in Parasitology 22(3): 123–128.
89. Dye, C. (1996) The logic of visceral leishmaniasis control. American Journal of Tropical
Medicine and Hygiene 55: 125–130.
90. Stephen, C. and Karesh, W.B. (2014) Is one health delivering results? Revue scientifique et
technique (International Office of Epizootics) 33(2): 375–379.
91. Smith, D.H., Pepin, J. and Stich, A.H.R. (1998) Human African trypanosomiasis: An emerging
public health crisis. British Medical Bulletin 54(2): 341–355.
Revisiting zoonotic human African trypanosomiasis control in Uganda
67© 2016 Macmillan Publishers Ltd. 0197-5897 Journal of Public Health Policy Vol. 37, 1, 51–67
Reproduced with permission of the copyright owner. Further reproduction prohibited without
permission.
